SciClone Q2 Revenue Up; Expects $35M to $36M for 2007
Moderate trading activity for SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) on the eve of its second quarter earnings announcement as the stock closed down 2 cents at $2.14 per share. SciClone reported its second quarter earnings before the opening bell today. For the second quarter 2007, product revenues from the sale of ZADAXIN (thymalfasin), SciClone's lead product, increased by 13 percent to $9 million, compared with revenues of $7.9 million for the second quarter 2006. The revenue numbers were in-line with analysts’ estimates of $8.97 million for the second quarter of 2007. The increase in product revenues for the second quarter…